.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
UBS
QuintilesIMS
Deloitte
McKinsey
Cantor Fitzgerald
Cerilliant
Covington
Express Scripts

Generated: January 17, 2018

DrugPatentWatch Database Preview

Patents Expiring in February 2017

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
RocheTAMIFLUoseltamivir phosphateCAPSULE;ORAL021087-003Jul 2, 2007ABRXYesNo➤ Subscribe➤ SubscribeY
RocheTAMIFLUoseltamivir phosphateFOR SUSPENSION;ORAL021246-002Mar 21, 2011ABRXYesYes➤ Subscribe➤ SubscribeY
RocheTAMIFLUoseltamivir phosphateCAPSULE;ORAL021087-001Oct 27, 1999ABRXYesYes➤ Subscribe➤ SubscribeY
RocheTAMIFLUoseltamivir phosphateCAPSULE;ORAL021087-002Jul 2, 2007ABRXYesNo➤ Subscribe➤ SubscribeY
Perrigo Pharma IntlEVAMISTestradiolSPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes➤ Subscribe➤ SubscribeYFEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
Perrigo Pharma IntlEVAMISTestradiolSPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes➤ Subscribe➤ SubscribeYMENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE)
Perrigo Pharma IntlEVAMISTestradiolSPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes➤ Subscribe➤ SubscribeYFEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
Eli Lilly And CoAXIRONtestosteroneSOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo➤ Subscribe➤ SubscribeYTESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
Eli Lilly And CoAXIRONtestosteroneSOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo➤ Subscribe➤ SubscribeYTESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
Eli Lilly And CoAXIRONtestosteroneSOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo➤ Subscribe➤ SubscribeYTESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Queensland Health
Boehringer Ingelheim
Colorcon
US Department of Justice
Covington
Cipla
Chinese Patent Office
Healthtrust
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot